Literature DB >> 33432066

Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.

Yuki Nakamura1, Shozo Yokoyama2, Kenji Matsuda1, Koichi Tamura1, Yasuyuki Mitani1, Hiromitsu Iwamoto1, Yuki Mizumoto1, Daisuke Murakami1, Yuji Kitahata1, Hiroki Yamaue1.   

Abstract

Preoperative ctDNA status in relation to recurrence in cases of CRC remains unclear. We examined preoperative ctDNA detection by targeting KRAS gene mutations as a predictive marker for recurrence after CRC surgery. We measured the preoperative KRAS mutated ctDNA status and analyzed the correlation with clinicopathologic features of 180 patients that underwent surgery for CRC. We studied the association between preoperative KRAS mutated ctDNA and postoperative recurrence in patients (n = 150) that underwent radical surgery. KRAS mutated ctDNA was detected in 59 patients (32.8%). Median mutant allele frequency of KRAS in ctDNA was 0.20%. KRAS status in ctDNA and lymph node metastasis and distant metastasis were not significantly different. Among patients that underwent radical resection, recurrence occurred in 21 (14.0%, median follow-up 24 months). In Kaplan-Meier analysis, preoperative detection of KRAS mutated ctDNA was associated with inferior recurrence-free interval (RFI) (p = 0.002) and recurrence-free survival (RFS) (p = 0.025). In a multivariate Cox proportional hazards model, preoperative detection of KRAS mutated ctDNA was an independent factor related to both RFI (HR = 3.08; p = 0.012) and RFS (HR = 2.18; p = 0.044). Preoperative measurement of KRAS mutated ctDNA could be useful to decide postoperative treatment.

Entities:  

Year:  2021        PMID: 33432066      PMCID: PMC7801374          DOI: 10.1038/s41598-020-79909-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  29 in total

1.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

2.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

Authors:  H J Andreyev; A R Norman; D Cunningham; J R Oates; P A Clarke
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

3.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Authors:  S Jahr; H Hentze; S Englisch; D Hardt; F O Fackelmayer; R D Hesch; R Knippers
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.

Authors:  Nick Beije; Jean C Helmijr; Marjolein J A Weerts; Corine M Beaufort; Matthew Wiggin; Andre Marziali; Cornelis Verhoef; Stefan Sleijfer; Maurice P H M Jansen; John W M Martens
Journal:  Mol Oncol       Date:  2016-12       Impact factor: 6.603

5.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Authors:  H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

6.  Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Authors:  D G Haller; M J O'Connell; T H Cartwright; C J Twelves; E F McKenna; W Sun; M W Saif; S Lee; G Yothers; H-J Schmoll
Journal:  Ann Oncol       Date:  2015-01-16       Impact factor: 32.976

Review 7.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

8.  Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.

Authors:  S Kruger; V Heinemann; C Ross; F Diehl; D Nagel; S Ormanns; S Liebmann; I Prinz-Bravin; C B Westphalen; M Haas; A Jung; T Kirchner; M von Bergwelt-Baildon; S Boeck; S Holdenrieder
Journal:  Ann Oncol       Date:  2018-12-01       Impact factor: 32.976

9.  KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Authors:  Francesco Sclafani; Ian Chau; David Cunningham; Jens C Hahne; George Vlachogiannis; Zakaria Eltahir; Andrea Lampis; Chiara Braconi; Eleftheria Kalaitzaki; David Gonzalez De Castro; Andrew Wotherspoon; Jaume Capdevila; Bengt Glimelius; Noelia Tarazona; Ruwaida Begum; Hazel Lote; Sanna Hulkki Wilson; Giulia Mentrasti; Gina Brown; Diana Tait; Jacqueline Oates; Nicola Valeri
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

10.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.

Authors:  Thomas Reinert; Tenna Vesterman Henriksen; Emil Christensen; Shruti Sharma; Raheleh Salari; Himanshu Sethi; Michael Knudsen; Iver Nordentoft; Hsin-Ta Wu; Antony S Tin; Mads Heilskov Rasmussen; Søren Vang; Svetlana Shchegrova; Amanda Frydendahl Boll Johansen; Ramya Srinivasan; Zoe Assaf; Mustafa Balcioglu; Alexander Olson; Scott Dashner; Dina Hafez; Samantha Navarro; Shruti Goel; Matthew Rabinowitz; Paul Billings; Styrmir Sigurjonsson; Lars Dyrskjøt; Ryan Swenerton; Alexey Aleshin; Søren Laurberg; Anders Husted Madsen; Anne-Sofie Kannerup; Katrine Stribolt; Søren Palmelund Krag; Lene H Iversen; Kåre Gotschalck Sunesen; Cheng-Ho Jimmy Lin; Bernhard G Zimmermann; Claus Lindbjerg Andersen
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 31.777

View more
  4 in total

Review 1.  Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review.

Authors:  Suzanna J Schraa; Karlijn L van Rooijen; Miriam Koopman; Geraldine R Vink; Remond J A Fijneman
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

2.  Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.

Authors:  Takaomi Hayashi; Yoichiro Yoshida; Teppei Yamada; Keita Tanaka; Hideki Shimaoka; Ryuji Kajitani; Taro Munechika; Hideki Nagano; Yoshiko Matsumoto; Akira Komono; Ryohei Sakamoto; Naoya Aisu; Gumpei Yoshimatsu; Fumihiro Yoshimura; Suguru Hasegawa
Journal:  Cancer Med       Date:  2022-03-21       Impact factor: 4.711

Review 3.  Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.

Authors:  Loretta László; Anita Kurilla; Tamás Takács; Gyöngyi Kudlik; Kitti Koprivanacz; László Buday; Virag Vas
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

Review 4.  Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer.

Authors:  Jun Gong; Andrew Hendifar; Alexandra Gangi; Karen Zaghiyan; Katelyn Atkins; Yosef Nasseri; Zuri Murrell; Jane C Figueiredo; Sarah Salvy; Robert Haile; Megan Hitchins
Journal:  Cancers (Basel)       Date:  2021-09-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.